While President-elect Donald Trump looks poised to scrap many policies of the Biden administration, one veteran analyst says ...

Leptin by itself doesn't hold promise for weight loss — but a new mouse study suggests it could work in combination with ...

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says - In the first ...

The rise of weight loss drugs is not only changing individual lives, but also reshaping large sections of the economy.

More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

The randomized clinical trial showed that Zepbound patients achieved 47% more relative weight loss than Wegovy patients.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has outperformed its main competitor, Wegovy, in a clinical ...

Ozempic promotes weight loss by mimicking the GLP-1 hormone the body naturally produces after eating, so users feel fuller ...

Millions of Americans with obesity would be eligible to have popular weight-loss drugs like Wegovy or Zepbound covered by ...

People who took Zepbound, Eli Lilly’s weight loss drug, shed more pounds than those on Novo Nordisk’s Wegovy in a clinical ...

W ith more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.